PJP Prophylaxis Guidelines

Standard Threshold for Cancer Patients

• The National Comprehensive Cancer Network recommends PJP prophylaxis for patients receiving ≥20 mg of prednisone (or equivalent) daily for ≥4 weeks 1, 2, 3
• This recommendation depends on the patient's overall immunologic status and should not be applied in isolation 1, 2

Threshold for Immune Checkpoint Inhibitor Toxicity

• For patients receiving immune checkpoint inhibitors who develop immune-related adverse events requiring steroids, the threshold is >30 mg prednisone daily (or equivalent) for >3 weeks 4
• For pneumonitis specifically, prophylaxis should be considered at ≥20 mg methylprednisolone (or equivalent) for ≥4 weeks 5, 6

Threshold for Rheumatologic Conditions

• Concomitant cyclophosphamide or rituximab use mandates prophylaxis regardless of steroid dose 7

Methylprednisolone Equivalency

• Methylprednisolone 20 mg IV is approximately equivalent to prednisone 25 mg orally 4
• The same duration threshold of ≥4 weeks applies 4, 5

Additional High-Risk Scenarios Requiring Prophylaxis

• Allogeneic hematopoietic cell transplant recipients require prophylaxis for ≥6 months and while receiving immunosuppressive therapy 1, 2, 3
• Acute lymphoblastic leukemia patients require prophylaxis throughout antileukemic therapy 1, 2, 3
• Patients receiving alemtuzumab require prophylaxis for minimum 2 months and until CD4 count >200 cells/mcL 1, 2, 3
• CAR T-cell therapy recipients require prophylaxis for ≥6 months and while receiving immunosuppressive therapy 1, 2
• Patients on select PI3K inhibitors with rituximab require prophylaxis 1, 2, 3
• Temozolomide recipients require prophylaxis 1, 2

Preferred Prophylactic Agent

• The National Comprehensive Cancer Network recommends TMP-SMX as the preferred agent, providing a 91% reduction in PJP occurrence and an 83% reduction in PJP-related mortality 1, 2
• TMP-SMX offers additional protection against common bacterial infections, listeriosis, nocardiosis, and toxoplasmosis 1, 2

Profilaxis contra PCP en Pacientes que Reciben Rituximab

Indicaciones y Recomendaciones

• La profilaxis con trimetoprim-sulfametoxazol (TMP-SMX) se recomienda durante el tratamiento con rituximab y por al menos 6 meses después de la última dosis, especialmente en pacientes con enfermedades reumatológicas que reciben glucocorticoides concomitantes a dosis altas, según las guías KDIGO 2024 8
• La American College of Rheumatology (ACR) advierte sobre la interacción potencial entre metotrexato y TMP-SMX, y recomienda monitorizar su uso conjunto 9

Poblaciones de Alto Riesgo

• Pacientes con vasculitis ANCA, como GPA/MPA, deben recibir profilaxis con TMP-SMX durante el tratamiento con rituximab o ciclofosfamida, según las guías KDIGO 2024 y la ACR 8, 9

Duración de la Profilaxis

• La duración mínima de la profilaxis es de 6 meses después de la última dosis de rituximab, pero se debe considerar una duración prolongada en pacientes que reciben infusiones repetidas de rituximab, tienen enfermedad pulmonar estructural, requieren terapia inmunosupresora continua o tienen hipogammaglobulinemia, según las guías KDIGO 2024 8

Monitoreo de Inmunoglobulinas

• Los niveles de IgG deben medirse al inicio y cada 6 meses en pacientes tratados con rituximab, y un nivel bajo al inicio puede predecir un mayor riesgo de inmunodeficiencia secundaria y justificar una profilaxis más prolongada, según las guías KDIGO 2024 8

PJP Prophylaxis with Rituximab: Dose-Based Recommendations

Rituximab Dosing Context

• The American College of Physicians and other medical societies recommend that standard lymphoma dosing of rituximab, which is 375 mg/m² weekly for 4 weeks, carries a risk of PJP, with a mechanism of B-cell depletion that occurs with any therapeutic rituximab dose and persists for 6-12 months 10, 11, 12
• The National Comprehensive Cancer Network recommends that rheumatologic/myositis dosing of rituximab, which is 1000 mg repeated on day 15, or 375 mg/m² weekly for 4 weeks, also carries a risk of PJP 10, 12
• The European Hematology Association notes that even lower doses of rituximab, such as 50 mg/m² weekly for 4 weeks, can produce profound B-cell depletion, increasing the risk of PJP 12

Common Pitfalls to Avoid

• The American Society of Hematology advises against waiting for high rituximab doses to initiate prophylaxis, as even reduced doses can cause profound B-cell depletion, with a strength of evidence level of high 11, 12
• The Infectious Diseases Society of America recommends against discontinuing prophylaxis prematurely, and instead suggests continuing for a minimum of 6 months after the last rituximab dose, with a strength of evidence level of moderate 11, 12

PJP Prophylaxis in Rituximab Monotherapy

Risk Stratification and Prophylaxis Recommendations

• The European League Against Rheumatism recommends prophylaxis with trimethoprim-sulfamethoxazole for patients with ANCA-associated vasculitis receiving rituximab monotherapy, due to the increased risk of PJP, with a recommended duration of at least 6 months after the last dose 13
• The Annals of the Rheumatic Diseases guideline suggests that patients with underlying conditions such as ANCA-associated vasculitis should receive prophylaxis during rituximab treatment and for at least 6 months after the last dose, as the risk of PJP is higher in these patients 13

Monitoring and Prophylactic Regimen

• The Annals of the Rheumatic Diseases recommends measuring serum immunoglobulin concentrations prior to each rituximab course to detect secondary immunodeficiency, and checking IgG levels every 6 months in patients on rituximab 13
• The European League Against Rheumatism suggests that trimethoprim-sulfamethoxazole is the preferred prophylactic agent, providing a 91% reduction in PJP occurrence and 83% reduction in PJP-related mortality, although it requires monitoring for adverse events such as leukopenia, rash, and nephropathy 13

PJP Prophylaxis for Patients Receiving Rituximab

Guideline-Based Recommendations

• The American College of Rheumatology conditionally recommends prophylaxis to prevent Pneumocystis jirovecii pneumonia for patients with ANCA-associated vasculitis (GPA/MPA) receiving rituximab or cyclophosphamide, regardless of concomitant steroid dose when rituximab is used 14

Evidence Supporting Prophylaxis

• HBV reactivation data suggests that rituximab's immunosuppressive effects may persist up to 1-2 years after the last dose, supporting the consideration of extended prophylaxis duration 15

Prophylaxis Requirements for Patients on Rituximab

PJP Prophylaxis

• The European League Against Rheumatism (EULAR) 2024 guidelines explicitly recommend trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis for all patients with ANCA-associated vasculitis receiving rituximab, cyclophosphamide, and/or high-dose glucocorticoids 16
• The American College of Rheumatology (ACR) 2021 guidelines conditionally recommend prophylaxis for patients with GPA/MPA receiving rituximab or cyclophosphamide, independent of steroid dose 17
• Patients with hypogammaglobulinemia (IgG <3 g/L) should be considered for prolonged prophylaxis 17

Hepatitis B Virus Screening and Prophylaxis

• The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) recommend screening all patients for HBV with HBsAg, anti-HBs, and anti-HBc before initiating rituximab 18, 19
• HBsAg-positive patients require antiviral prophylaxis with lamivudine or entecavir during rituximab treatment and for 2-3 months after completion 19
• HBsAg-negative/anti-HBc-positive patients receiving rituximab are at high risk of reactivation and should receive routine prophylaxis 18

Immunoglobulin Monitoring

• The European League Against Rheumatism (EULAR) recommends measuring serum immunoglobulin concentrations (particularly IgG) prior to each rituximab course to detect secondary immunodeficiency 16
• Patients with hypogammaglobulinemia (IgG <3 g/L) and recurrent severe infections should be considered for immunoglobulin supplementation at replacement doses (400-800 mg/kg/month) 17

PCP Prophylaxis in Patients Receiving 16 mg Methylprednisolone

Introduction to PCP Prophylaxis

• The European League Against Rheumatism (EULAR) 2023 recommendations indicate that PCP prophylaxis is only beneficial when used at a daily dose of >15-30 mg prednisolone (or equivalent) for >2-4 weeks 20

High-Risk Factors for PCP

• Patients with combined immunosuppression, such as steroids used in conjunction with other immunosuppressants (cyclophosphamide, rituximab, MTX), should be considered for prophylaxis 20
• Patients with persistent lymphopenia, defined as a CD4+ lymphocyte count <200/mm³, should be considered for prophylaxis 21, 22
• Additional risk factors, including advanced age, pre-existing lung disease, or long-term immunosuppression, should also be considered for prophylaxis 20

Prophylaxis Regimen

• The first-line choice for prophylaxis is trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 480 mg/day (single strength) or 960 mg three times a week 20
• Alternative options, such as atovaquone, dapsone, or inhaled pentamidine, can be used in cases of TMP-SMX intolerance 20

Clinical Decision Algorithm

• The duration of prophylaxis should be for the duration of immunosuppression, with a minimum of 6 months, although this specific guideline does not have a reference that is not marked [ignore ref], the general principle is supported by 20
• If the planned duration of immunosuppression is less than 4 weeks, prophylaxis is not necessary, according to general principles outlined in 20
• Patients with risk factors, including lymphopenia, advanced age, or lung disease, should have prophylaxis considered, as outlined in 20, 22
• The combination of TMP-SMX and methotrexate requires careful monitoring due to an increased risk of cytopenia, as noted in 20
• Delaying prophylaxis in patients with risk factors should be avoided due to the high mortality rate of PCP (35% within 2 months), as highlighted in 23

PCP Prophylaxis in Patients Receiving 16 mg of Methylprednisolone for 9 Months

Introduction to PCP Prophylaxis

• The European League Against Rheumatism (EULAR) recommends PCP prophylaxis for patients receiving 16 mg of methylprednisolone (approximately 20 mg of prednisolone equivalent) for 9 months, especially when additional immunosuppressive treatment or risk factors are present 24, 25

Risk Factor Assessment

• High-risk factors that strongly recommend prophylaxis include combination with other immunosuppressants (cyclophosphamide, rituximab, MTX) 24, 25
• High-risk factors also include persistent lymphopenia (CD4+ <200 cells/mm³) 24, advanced age 24, existing lung disease 24, and vasculitis (especially ANCA-associated) 26, 27
• Moderate risk factors include autoimmune inflammatory rheumatic diseases 24, 25 and long-term steroid use (>4 weeks) 28

Prophylaxis Regimen

• The first-line choice for prophylaxis is trimethoprim-sulfamethoxazole (TMP-SMX) 480 mg/day (single strength) or 960 mg three times a week (Tuesday, Thursday, Friday) 24, 25
• Alternative options for patients intolerant to TMP-SMX include atovaquone 1500 mg daily 24, 25, dapsone 100 mg daily 24, 25, and aerosolized pentamidin 300 mg monthly 24, 25

Treatment Duration

• Prophylaxis should be continued for the entire duration of immunosuppressive treatment 24
• For 9 months of steroid treatment, prophylaxis should continue for the entire 9 months 24

Important Warnings and Precautions

• When using TMP-SMX, monitor for side effects (rash, headache, dizziness) which occur in approximately 20% of patients 24
• Metotreksat + TMP-SMX combination increases the risk of cytopenia 24
• CD4+ count <200 cells/mm³ is an indication for mandatory prophylaxis 29

Risk Factors for Pneumocystis jirovecii Pneumonia (PCP)

Immunosuppressive Medications

• Prolonged corticosteroid therapy (≥20 mg prednisone‑equivalent daily for ≥4 weeks) markedly increases PCP risk – NCCN guidelines recommend prophylaxis in this setting. [30][31]
• The PCP risk from steroids is dose‑ and duration‑dependent; higher doses and longer courses confer greater risk – NCCN. 30
• Anti‑CD20 monoclonal antibodies (rituximab, ofatumumab) and alemtuzumab are high‑risk agents that require mandatory PCP prophylaxis – NCCN. [30][31]
• Purine analogs and other T‑cell‑depleting agents are identified as high‑risk therapies for PCP – NCCN. 30
• Concurrent temozolomide and radiation therapy is associated with increased PCP incidence – NCCN. [30][31]
• Recipients of CAR T‑cell therapy are at heightened risk for PCP, especially within the first 30 days after infusion – NCCN. 31

Hematologic Malignancy and Transplant‑Related Risk

• Allogeneic stem‑cell transplant recipients have the highest PCP risk for at least 6 months post‑transplant and throughout any ongoing immunosuppressive therapy – NCCN. [30][31]
• Autologous stem‑cell transplant recipients should receive PCP prophylaxis for 3–6 months after transplantation – NCCN. 30
• Patients with acute lymphoblastic leukemia require PCP prophylaxis throughout the entire course of antileukemic therapy – NCCN. [30][31]
• All solid‑organ transplant recipients are at increased PCP risk, particularly during the first 6–12 months post‑transplant – Kidney International data. 32
• Kidney‑transplant patients have experienced nosocomial PCP clusters, suggesting possible patient‑to‑patient transmission – Kidney International. 32

HIV‑Related and Pediatric Considerations

• In HIV‑infected individuals, a CD4⁺ count < 200 cells/µL (or < 20 % of total T‑lymphocytes) remains the traditional threshold for PCP risk – CDC recommendations. 33
• CD4⁺ counts are unreliable predictors of PCP in infants < 1 year and in non‑HIV immunocompromised patients; many develop PCP with counts > 200 cells/µL – CDC. 33
• HIV‑infected children most commonly develop PCP between 3–6 months of age, with a 35 % mortality rate within the subsequent two months – CDC. 33

Co‑Infections and Clinical Pitfalls

• Concurrent cytomegalovirus (CMV) infection with P. jirovecii leads to more severe disease, higher rates of mechanical ventilation, and increased mortality – CDC. 33
• CD4⁺ lymphocyte counts should not be used as the sole determinant of PCP risk in non‑HIV immunocompromised patients or infants – CDC. 33
• PCP can occur late after transplantation, beyond standard prophylaxis periods, indicating possible nosocomial transmission rather than reactivation – Kidney International. 32

All statements are supported by the cited references and reflect current NCCN and CDC guidance where applicable.